Novel Gene Set Enrichment Meta-Analysis reveals insights in SLE and Parkinson's Disease, controlling false positive rates effectively.
The proliferation of omics datasets in public repositories has created unprecedented opportunities for biomedical research but has also posed significant challenges for their integration, particularly due to missing genes and platform-specific discrepancies. Traditional gene expression meta-analysis often focuses on individual genes, leading to data loss and limited biological insights when there are missing genes across different studies. To address these limitations, we propose GSEMA (Gene Set Enrichment Meta-Analysis), a novel methodology that leverages single-sample enrichment scoring to aggregate gene expression data into pathway-level matrices. By applying meta-analysis techniques to enrichment scores, GSEMA preserves the magnitude and directionality of effects, enabling the definition of pathway activity across datasets. Using simulated data and case studies on Systemic Lupus Erythematosus (SLE) and Parkinson's Disease (PD), we demonstrate that GSEMA outperforms other methods in controlling false positive rates while providing meaningful biological interpretations. GSEMA methodology is implemented as an R package available on CRAN repository.
No takes yet. Share an insight, caveat, or question.
García et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: